# Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy

> **NCT02292472** · PHASE2 · COMPLETED · sponsor: **Medy-Tox** · enrollment: 69 (actual)

## Conditions studied

- Hypertrophy of Masseter Muscle

## Interventions

- **DRUG:** Botulinum Toxin Type A
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT02292472
- **Lead sponsor:** Medy-Tox
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-06
- **Primary completion:** 2015-05-24
- **Final completion:** 2015-08-24
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2019-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02292472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02292472, "Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02292472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*